Program Head: Francesco Bertoni, MD
The mission of the Lymphoma and Genomics Research Program is to pursue research bridging basic and clinical aspects of the genesis, progression, prognosis, and treatment of Lymphoma. Research focuses on molecular and genomic determinants of cancer predisposition, tumor development and metastasis, the nature of therapeutic targets and the basis for their response to therapy. It draws from fundamental mechanisms of cell and tissue development, animal models of the disease, and clinical samples and studies.
1. Bertoni Group – Lymphoma Genomics
- Development of new anti-lymphoma compounds and lymphoma genomics
2. Rossi Group – Experimental Hematology
The research topic of the Laboratory of Experimental Hematology is the molecular pathogenesis of mature B-cell tumors and translation of biological information into markers for disease diagnosis, prognostication and treatment. Original and ground-breaking contributions of the proponent in the field of mature B-cell tumors have been incorporated in current disease guidelines and the in WHO Classification of lymphoid malignancies, which the proponent co-authored. The research of the Laboratory of Experimental Hematology is supported by the European Research Council , the Swiss National Science Foundation, the National Swiss Cancer League, the Nelia and Amadeo Barletta Foundation, the Ticino Cancer League.
The fundamental research of the Laboratory of Experimental Hematology include:
- The genetics of marginal zone lymphomas
- The biological mechanisms underlying residual disease persistence in chronic lymphocytic leukemia (IOSI-EMA-001 and SAKK 34/17 clinical trials)
The translational research of the Laboratory of Experimental Hematology include:
- The development of liquid biopsy as tool to monitor residual and chemoresistant disease in aggressive lymphomas (IOSI-EMA-003 trial)
- The development and validation of prognostic models in chronic lymphocytic leukemia, follicular lymphoma and splenic marginal zone lymphoma (IOSI-EMA-004, IOSI-EMA-005 and clinical IELSG46 trials)